Inventor
Celeste RICHARDSON
Inventor
US
Overview
Patents· 5 as inventor
Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.
A61Kprimary
A61KPreparations for medical, dental or toiletry purposes20%
A61PSpecific therapeutic activity of chemical compounds or medicinal preparations20%
C07KPeptides20%
C12NMicroorganisms or enzymes16%
Y02ATechnologies for adaptation to climate change12%
C12YEnzymes8%
C07HSugars4%
PatentTitleYear
12,338,287Treatment of cancer using a CD33 chimeric antigen receptor202512,214,037Treatment of cancer using humanized anti-BCMA chimeric antigen receptor202512,037,583Compositions and methods for immunooncology202411,666,642PDE5 compositions and methods for immunotherapy202311,241,485PDE5 compositions and methods for immunotherapy2022Career & activity timeline
Assembled from patent assignee/location history and declaration credentials.
2022–2023Patents assigned to OBSIDIAN THERAPEUTICS INC (2)· patent assignee history
2022–2025Based in US· patent location history
2024–2025Patents assigned to NOVARTIS AG (3)· patent assignee history
2024Patents assigned to INTELLIA THERAPEUTICS INC (1)· patent assignee history
2025Patents assigned to UNIV PENNSYLVANIA (2)· patent assignee history
Inventor activity
Assignee and location history derived from the patent record.
Assignees
| Assignee | Patents | Span |
|---|---|---|
| NOVARTIS AG | 3 | 2024–2025 |
| OBSIDIAN THERAPEUTICS INC | 2 | 2022–2023 |
| UNIV PENNSYLVANIA | 2 | 2025 |
| INTELLIA THERAPEUTICS INC | 1 | 2024 |
Locations
| Location | Patents | Span |
|---|---|---|
| US | 5 | 2022–2025 |